Biolife Solutions (BLFS) 2.14 $BLFS
BioLife Solutions Launches New Cell Thawing Media Products in Response to Worldwide Shortage of Dextran Solutions
PR Newswire - Wed Feb 11, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that it has commenced GMP manufacturing of low molecular weight (LMD) Dextran solutions for use in thawing human cells after cryopreservation. The Company has launched these new products in response to inquiries from numerous customers and clinicians who have been subjected to an extended worldwide shortage of dextran solutions that are used off-label to transition frozen cells to room temperature.
BLFS: 2.14 (+0.06)
Update: BioLife Announces Preliminary Revenues For 2014
Trevor Lowenthal - at Seeking Alpha - Tue Jan 13, 12:50AM CST
BLFS: 2.14 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.94 (+0.10), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), ARWR: 6.77 (+0.21), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), NADL: 2.10 (-0.02), TIF: 89.05 (+0.95), BITA: 62.95 (+2.85), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), TOPS: 1.14 (+0.02), IRMD: 14.61 (-0.35), FMI: 48.88 (+0.17), SRPT: 12.76 (+0.11), REXX: 5.08 (+0.13), LOCM: 0.65 (-0.03), BLFS: 2.14 (+0.06), SNDK: 82.81 (+0.51), AWX: 3.50 (+0.10)
BioLife reports preliminary results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:13AM CST
BLFS: 2.14 (+0.06)
BioLife Solutions Reports Preliminary Revenue for 2014
PR Newswire - Mon Jan 12, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced preliminary revenue for the fourth quarter and full year 2014 and a recap of operational accomplishments.
BLFS: 2.14 (+0.06)
Update: BioLife Establishes 75 Embedded Clinical Trials In 2014
Trevor Lowenthal - at Seeking Alpha - Tue Jan 06, 4:33PM CST
BLFS: 2.14 (+0.06)
BioLife Solutions Biopreservation Media Products Embedded in 175 Cellular Immunotherapy & Other Regenerative Medicine Clinical Trials
PR Newswire - Mon Jan 05, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today provided an update on the adoption of its HypoThermosol and CryoStor biopreservation media products in a greatly increased number of customer clinical trials of novel cellular immunotherapies and other cell-based approaches for treating and possibly curing the leading causes of death and disorders throughout the world.
BLFS: 2.14 (+0.06)
BioLife Solutions Sets Date for Annual Meeting of Stockholders
PR Newswire - Wed Dec 24, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced that it will hold its 2015 Annual Meeting of Stockholders on May 4, 2015 (the "Annual Meeting" .
BLFS: 2.14 (+0.06)
BioLife Solutions Names Pharmaceutical Industry Expert Kevin O'Donnell as Vice President, Cold Chain Standards, Practices & Compliance
PR Newswire - Tue Dec 23, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced that pharmaceutical industry cold chain expert Kevin O'Donnell has joined the Company as Vice President, Cold Chain Standards, Practices & Compliance.
BLFS: 2.14 (+0.06)
BioLife Solutions to Present at the LD Micro "Main Event" Investor Conference on Wednesday, December 3, 2014
PR Newswire - Tue Nov 25, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced that it will be presenting at the LD MICRO "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California.
BLFS: 2.14 (+0.06)
BUYINS.NET Issues BioLife Solutions (BLFS) SqueezeTrigger Report
M2 - Mon Nov 24, 7:09AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated trading coverage on BioLife Solutions, Inc., (NASDAQ: BLFS) after releasing the latest short sale data through November 21, 2014. The total aggregate number of shares shorted since August 2009 is approximately 3.4 million shares, adjusted for a 1 for 14 reverse split that occurred on January 29, 2014. Approximately 26.04% of daily trading volume is short selling. The SqueezeTrigger price for all BLFS shares shorted is $3.29. A short squeeze is expected to begin when shares of BLFS close above the $3.29 SqueezeTrigger price.
BLFS: 2.14 (+0.06)
BioLife Solutions Launches Two New Product Packaging Options for BloodStor® and CryoStor® Freeze Media
PR Newswire - Mon Nov 17, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced it has launched two new improved packaging options for its BloodStor and CryoStor cryopreservation freeze media products.
BLFS: 2.14 (+0.06)
BioLife Solutions Named to Deloitte's 2014 Technology Fast 500(TM) List of Fastest Growing Companies in North America
PR Newswire - Thu Nov 13, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced it has been named to the Deloitte 2014 Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This is the second consecutive year BioLife has been recognized for high growth.
BLFS: 2.14 (+0.06)
BioLife Solutions' (BLFS) CEO Mike Rice on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 10:23PM CST
BLFS: 2.14 (+0.06)
Update: BioLife Q3 Earnings
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 5:00AM CST
BLFS: 2.14 (+0.06)
BioLife Solutions misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:34PM CST
BLFS: 2.14 (+0.06)
BioLife Solutions Announces Third Quarter 2014 Results
PR Newswire - Thu Nov 06, 3:05PM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced financial results for the third quarter of 2014.
BLFS: 2.14 (+0.06)
BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014
PR Newswire - Thu Oct 30, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced today that the Company's third quarter 2014 financial results will be released on Thursday, November 6, 2014, and that the Company will host a conference call and live webcast at 1:30 p.m. PST that afternoon. Management will provide an overview of the Company's financial results and a general business update.
BLFS: 2.14 (+0.06)
RoosterBio Selects BioLife Solutions CryoStor® to Commercialize Human Bone Marrow-Derived Stem Cells
PR Newswire - Tue Oct 21, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , announced today that Frederick, MD based RoosterBio, Inc., has adopted the Company's CryoStor clinical grade cryopreservation freeze media to commercialize RoosterBio's human bone marrow-derived, adult mesenchymal stem cell (hMSC) products. RoosterBio's hMSC products are being used by researchers throughout the world to accelerate the development of cellular therapies and engineered tissues targeting major diseases and disorders affecting millions of patients each year.
BLFS: 2.14 (+0.06)
BioLife Solutions Launches New Cell Thawing Media Products in Response to Worldwide Shortage of Dextran Solutions
PR Newswire - Wed Feb 11, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that it has commenced GMP manufacturing of low molecular weight (LMD) Dextran solutions for use in thawing human cells after cryopreservation. The Company has launched these new products in response to inquiries from numerous customers and clinicians who have been subjected to an extended worldwide shortage of dextran solutions that are used off-label to transition frozen cells to room temperature. BLFS: 2.14 (+0.06)
Update: BioLife Announces Preliminary Revenues For 2014
Trevor Lowenthal - at Seeking Alpha - Tue Jan 13, 12:50AM CST
BLFS: 2.14 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.94 (+0.10), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), ARWR: 6.77 (+0.21), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), NADL: 2.10 (-0.02), TIF: 89.05 (+0.95), BITA: 62.95 (+2.85), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), TOPS: 1.14 (+0.02), IRMD: 14.61 (-0.35), FMI: 48.88 (+0.17), SRPT: 12.76 (+0.11), REXX: 5.08 (+0.13), LOCM: 0.65 (-0.03), BLFS: 2.14 (+0.06), SNDK: 82.81 (+0.51), AWX: 3.50 (+0.10)
BioLife reports preliminary results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:13AM CST
BLFS: 2.14 (+0.06)
BioLife Solutions Reports Preliminary Revenue for 2014
PR Newswire - Mon Jan 12, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced preliminary revenue for the fourth quarter and full year 2014 and a recap of operational accomplishments. BLFS: 2.14 (+0.06)
Update: BioLife Establishes 75 Embedded Clinical Trials In 2014
Trevor Lowenthal - at Seeking Alpha - Tue Jan 06, 4:33PM CST
BLFS: 2.14 (+0.06)
BioLife Solutions Biopreservation Media Products Embedded in 175 Cellular Immunotherapy & Other Regenerative Medicine Clinical Trials
PR Newswire - Mon Jan 05, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today provided an update on the adoption of its HypoThermosol and CryoStor biopreservation media products in a greatly increased number of customer clinical trials of novel cellular immunotherapies and other cell-based approaches for treating and possibly curing the leading causes of death and disorders throughout the world. BLFS: 2.14 (+0.06)
BioLife Solutions Sets Date for Annual Meeting of Stockholders
PR Newswire - Wed Dec 24, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that it will hold its 2015 Annual Meeting of Stockholders on May 4, 2015 (the "Annual Meeting" . BLFS: 2.14 (+0.06)
BioLife Solutions Names Pharmaceutical Industry Expert Kevin O'Donnell as Vice President, Cold Chain Standards, Practices & Compliance
PR Newswire - Tue Dec 23, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that pharmaceutical industry cold chain expert Kevin O'Donnell has joined the Company as Vice President, Cold Chain Standards, Practices & Compliance. BLFS: 2.14 (+0.06)
BioLife Solutions to Present at the LD Micro "Main Event" Investor Conference on Wednesday, December 3, 2014
PR Newswire - Tue Nov 25, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that it will be presenting at the LD MICRO "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California. BLFS: 2.14 (+0.06)
BUYINS.NET Issues BioLife Solutions (BLFS) SqueezeTrigger Report
M2 - Mon Nov 24, 7:09AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated trading coverage on BioLife Solutions, Inc., (NASDAQ: BLFS) after releasing the latest short sale data through November 21, 2014. The total aggregate number of shares shorted since August 2009 is approximately 3.4 million shares, adjusted for a 1 for 14 reverse split that occurred on January 29, 2014. Approximately 26.04% of daily trading volume is short selling. The SqueezeTrigger price for all BLFS shares shorted is $3.29. A short squeeze is expected to begin when shares of BLFS close above the $3.29 SqueezeTrigger price.
BLFS: 2.14 (+0.06)
BioLife Solutions Launches Two New Product Packaging Options for BloodStor® and CryoStor® Freeze Media
PR Newswire - Mon Nov 17, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced it has launched two new improved packaging options for its BloodStor and CryoStor cryopreservation freeze media products. BLFS: 2.14 (+0.06)
BioLife Solutions Named to Deloitte's 2014 Technology Fast 500(TM) List of Fastest Growing Companies in North America
PR Newswire - Thu Nov 13, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced it has been named to the Deloitte 2014 Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This is the second consecutive year BioLife has been recognized for high growth. BLFS: 2.14 (+0.06)
BioLife Solutions' (BLFS) CEO Mike Rice on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 10:23PM CST
BLFS: 2.14 (+0.06)
Update: BioLife Q3 Earnings
Trevor Lowenthal - at Seeking Alpha - Fri Nov 07, 5:00AM CST
BLFS: 2.14 (+0.06)
BioLife Solutions misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:34PM CST
BLFS: 2.14 (+0.06)
BioLife Solutions Announces Third Quarter 2014 Results
PR Newswire - Thu Nov 06, 3:05PM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced financial results for the third quarter of 2014. BLFS: 2.14 (+0.06)
BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014
PR Newswire - Thu Oct 30, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced today that the Company's third quarter 2014 financial results will be released on Thursday, November 6, 2014, and that the Company will host a conference call and live webcast at 1:30 p.m. PST that afternoon. Management will provide an overview of the Company's financial results and a general business update.
BLFS: 2.14 (+0.06)
RoosterBio Selects BioLife Solutions CryoStor® to Commercialize Human Bone Marrow-Derived Stem Cells
PR Newswire - Tue Oct 21, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, announced today that Frederick, MD based RoosterBio, Inc., has adopted the Company's CryoStor clinical grade cryopreservation freeze media to commercialize RoosterBio's human bone marrow-derived, adult mesenchymal stem cell (hMSC) products. RoosterBio's hMSC products are being used by researchers throughout the world to accelerate the development of cellular therapies and engineered tissues targeting major diseases and disorders affecting millions of patients each year. BLFS: 2.14 (+0.06)
